“Qol-ESC RevMDS“, phase II, multicenter, single-arm study. (Eudract number 2008-000547-34)
The aim of the clinical trial was to evaluate the efficacy of lenalidomide treatment in adult patients with anemia due to a low or intermediate risk of Mielodisplastic Syndrome with cytogenetic abnormal short arm delation of chromosome 5.
In addition to the evaluation of hematologic, cytogenetic and molecular response and toxicity, the response to the quality of life was evaluated.
For the study results, see the following publications:
Oliva EN, Cuzzola M., Nobile F., et al. Changes in RPS14 expression levels during lenalidomide treatment in Low-and Intermediate-1-risk Myelodysplastic. European Journal Of Haematology 85(3):231-5 • September 2010
Oliva EN., Cuzzola M., Aloe Spiriti MA, et al., Biological Activity of lenalidomide in myelodysplastic sindromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol. 2012 Sep 16. https://link.springer.com/article/10.1007/s00277-012-1569-0,
Oliva EN., Latagliata R., Laganà C., et al. Lenalidomide in Low-and Intermediate-1 IPSS risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety, and afficacy. Leuk Lymphoma. 2013 Feb 25. https://www.ncbi.nlm.nih.gov/pubmed/23432724,